Official Title
1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
Brief Summary

This is observational study to assess the prognosis of patients hospitalized with COVID-19 confirmed by RT-PCR and exposed to trimethylxanthine (TMX). Trimethylxanthine is the active molecule present in coffee. Due to the lack of etiologic treatments and considering interest about old treatments as an avenue for research, we conducted a comparative study aiming to evaluate the effect of 1,3,7-trimethylxanthine on COVID-19 infected patients. This is actually a study about methodology. The objective of this study is therefore not to demonstrate the effect of the substance on the disease but the importance of a rigorous methodology in scientific research. This project is called "Method and Teaching of Scientific Studies".

Unknown status
Coronavirus Disease 2019

Other: Data collection

Only data collection

Eligibility Criteria

Inclusion Criteria:

- Age > 18,

- No Trimethylxanthine contraindications (defined as allergy, previous reported
secondary effects),

- Infectious Disease Unit admission.

Exclusion Criteria:

- Secondary effects about Trimethylxanthine,

- Refuse to participate

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 100 Years
Contacts

Alexandre BLEIBTREU
142163303 - 0033
alexandre.bleibtreu@aphp.fr

Poitiers University Hospital
NCT Number
MeSH Terms
COVID-19